|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/27/23 Anavex Life Sciences Corp. 10-K 9/30/23 54:5.7M Electro Filings LLC/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.78M
2: EX-14.1 Code of Ethics HTML 151K
3: EX-21.1 Subsidiaries List HTML 15K
4: EX-23.1 Consent of Expert or Counsel HTML 15K
5: EX-23.2 Consent of Expert or Counsel HTML 15K
9: EX-97.1 Clawback Policy re: Recovery of Erroneously HTML 36K
Awarded Compensation
6: EX-31.1 Certification -- §302 - SOA'02 HTML 22K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 22K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 19K
15: R1 Cover HTML 89K
16: R2 Consolidated Balance Sheets HTML 73K
17: R3 Consolidated Balance Sheets (Parenthetical) HTML 30K
18: R4 Consolidated Statements of Operations and HTML 60K
Comprehensive Loss
19: R5 Consolidated Statements of Operations and HTML 33K
Comprehensive Loss (Parenthetical)
20: R6 Consolidated Statements of Cash Flows HTML 71K
21: R7 Consolidated Statements of Changes in HTML 77K
Stockholders' Equity
22: R8 Business Description and Basis of Presentation HTML 25K
23: R9 Summary of Significant Accounting Policies HTML 60K
24: R10 Accrued Liabilities HTML 29K
25: R11 Other Income HTML 30K
26: R12 Equity Offerings HTML 47K
27: R13 Commitments and Contingencies HTML 191K
28: R14 Income Taxes HTML 89K
29: R15 Subsequent Events HTML 20K
30: R16 Summary of Significant Accounting Policies HTML 95K
(Policies)
31: R17 Accrued Liabilities (Tables) HTML 28K
32: R18 Commitments and Contingencies (Tables) HTML 177K
33: R19 Income Taxes (Tables) HTML 75K
34: R20 Summary of Significant Accounting Policies HTML 20K
(Details Narrative)
35: R21 Accrued Liabilities (Details) HTML 27K
36: R22 Other Income (Details Narrative) HTML 30K
37: R23 Equity Offerings (Details Narrative) HTML 68K
38: R24 Commitments and Contingencies (Details) HTML 18K
39: R25 Commitments and Contingencies (Details 1) HTML 18K
40: R26 Commitments and Contingencies (Details 2) HTML 36K
41: R27 Commitments and Contingencies (Details 3) HTML 61K
42: R28 Commitments and Contingencies (Details 4) HTML 60K
43: R29 Commitments and Contingencies (Details 5) HTML 24K
44: R30 Commitments and Contingencies (Details 6) HTML 25K
45: R31 Commitments and Contingencies (Details Narrative) HTML 60K
46: R32 Income Taxes (Details) HTML 25K
47: R33 Income Taxes (Details 1) HTML 34K
48: R34 Income Taxes (Details 2) HTML 47K
49: R35 Income Taxes (Details Narrative) HTML 42K
52: XML IDEA XML File -- Filing Summary XML 83K
50: XML XBRL Instance -- e5240_10k_htm XML 1.03M
51: EXCEL IDEA Workbook of Financial Report Info XLSX 90K
11: EX-101.CAL XBRL Calculations -- avxl-20230930_cal XML 93K
12: EX-101.DEF XBRL Definitions -- avxl-20230930_def XML 240K
13: EX-101.LAB XBRL Labels -- avxl-20230930_lab XML 629K
14: EX-101.PRE XBRL Presentations -- avxl-20230930_pre XML 467K
10: EX-101.SCH XBRL Schema -- avxl-20230930 XSD 106K
53: JSON XBRL Instance as JSON Data -- MetaLinks 274± 387K
54: ZIP XBRL Zipped Folder -- 0001731122-23-002197-xbrl Zip 454K
EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Anavex Life Sciences Corp. (the “Company”) on Form 10-K for the fiscal year ending September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, in the capacities and on the date indicated below, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his or her knowledge:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| Date: November 27, 2023 | |
| /s/ Christopher Missling | |
| Christopher Missling, PhD | |
Chief Executive Officer, President, Secretary (Principal Executive Officer) |
| /s/ Sandra Boenisch | |
| Sandra Boenisch, CPA, CGA | |
| Principal Financial Officer, Treasurer (Principal Financial and Accounting Officer) |
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/27/23 | None on these Dates | ||
| For Period end: | 9/30/23 | |||
| List all Filings | ||||